JP2003509470A5 - - Google Patents

Download PDF

Info

Publication number
JP2003509470A5
JP2003509470A5 JP2001524625A JP2001524625A JP2003509470A5 JP 2003509470 A5 JP2003509470 A5 JP 2003509470A5 JP 2001524625 A JP2001524625 A JP 2001524625A JP 2001524625 A JP2001524625 A JP 2001524625A JP 2003509470 A5 JP2003509470 A5 JP 2003509470A5
Authority
JP
Japan
Prior art keywords
antigen
epitope
administration
combination
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001524625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003509470A (ja
Filing date
Publication date
Priority claimed from GBGB9922361.2A external-priority patent/GB9922361D0/en
Application filed filed Critical
Publication of JP2003509470A publication Critical patent/JP2003509470A/ja
Publication of JP2003509470A5 publication Critical patent/JP2003509470A5/ja
Withdrawn legal-status Critical Current

Links

JP2001524625A 1999-09-21 2000-09-20 抗原に対するcd8+t細胞免疫応答を増強するための複製欠損性アデノウイルスベクターの使用 Withdrawn JP2003509470A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
GB9922361.2 1999-09-21
PCT/GB2000/003601 WO2001021201A2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen

Publications (2)

Publication Number Publication Date
JP2003509470A JP2003509470A (ja) 2003-03-11
JP2003509470A5 true JP2003509470A5 (https=) 2007-10-18

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001524625A Withdrawn JP2003509470A (ja) 1999-09-21 2000-09-20 抗原に対するcd8+t細胞免疫応答を増強するための複製欠損性アデノウイルスベクターの使用

Country Status (12)

Country Link
EP (2) EP1612269A1 (https=)
JP (1) JP2003509470A (https=)
CN (1) CN1391609A (https=)
AT (1) ATE295421T1 (https=)
AU (1) AU762894B2 (https=)
BR (1) BR0014138A (https=)
CA (1) CA2384806A1 (https=)
DE (1) DE60020136T2 (https=)
DK (1) DK1214416T3 (https=)
ES (1) ES2241653T3 (https=)
GB (1) GB9922361D0 (https=)
WO (1) WO2001021201A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
CA2378539A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20050123561A1 (en) * 2002-05-20 2005-06-09 Mitsuo Honda Radio lan access authentication system
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
KR20090080941A (ko) * 2006-11-17 2009-07-27 제네트로닉스, 인코포레이티드 전기천공법을 이용한 백신접종 및 부스팅을 사용하여 면역 반응을 강화시키는 방법들
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
EP2198020B1 (en) * 2007-09-14 2016-04-13 Institut Pasteur Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use
GB0823497D0 (en) 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
US9828414B2 (en) * 2012-10-28 2017-11-28 Bavarian Nordic A/S Pr13.5 promoter for robust T-cell and antibody responses
CA3056542A1 (en) 2017-03-15 2018-09-20 Oxford Biomedica (Uk) Limited Method
WO2021074648A1 (en) * 2019-10-16 2021-04-22 Cancer Research Technology Limited Vector for cancer treatment
EP4444347A1 (en) 2021-12-07 2024-10-16 Barinthus Biotherapeutics (UK) Limited Vaccine boost methods and compositions
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine

Similar Documents

Publication Publication Date Title
JP2003509470A5 (https=)
Ertl et al. Novel vaccine approaches
JP2001081042A5 (https=)
Ulmer et al. DNA vaccines
EP0979284B2 (en) Reagents for vaccination which generate a cd8 t cell immune response
JP2004509149A5 (https=)
JP2004511201A5 (https=)
JP2002542827A5 (https=)
JP2005508916A5 (https=)
GB2384709A (en) Vaccination method
JP2006501825A5 (https=)
JP2000516200A (ja) ウシの呼吸病に対するポリヌクレオチドワクチン処方
JP2003530307A5 (https=)
Plotkin Six revolutions in vaccinology
JP2016513115A5 (https=)
CA2419822A1 (en) Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
JP2004501650A5 (https=)
JP2003519197A5 (https=)
JP2024105526A5 (https=)
GB9922361D0 (en) Generating an immune response to an antigen
WO2014063601A1 (zh) 诱导肿瘤特异性免疫的疫苗及其应用
JP2021528367A5 (https=)
JP2010523138A5 (https=)
WO2000063406A3 (en) Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
JP2002502827A5 (https=)